Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?

Authors

  • Dolores Grosso DNP, CRNP,

    1. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania
    Search for more papers by this author
  • Mark A. Weiss MD

    Corresponding author
    1. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania
    • Corresponding author: Mark Weiss, MD, Department of Medical Oncology, Thomas Jefferson University, 834 Chestnut St, Suite 320, Philadelphia, PA 19107; Fax: (215) 955-9641; mark.weiss@jefferson.edu

    Search for more papers by this author

  • See referenced original article on pages 1010–7, this issue.

Abstract

For over 2 decades, a series of clinical trials has tested the efficacy of interleukin-2 as postremission therapy for patients with acute myeloid leukemia. In this issue, Kolitz et al describe a large clinical trial testing this hypothesis that ultimately failed to answer the question because of patients failing to complete the prescribed therapy.

Ancillary